Literature DB >> 25902749

Prostaglandin E₂ and polyenylphosphatidylcholine: stiff competition for the fibrotic complications of inflammatory bowel disease?

Steven K Huang1, Marc Peters-Golden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25902749      PMCID： PMC4830265          DOI： 10.1007/s10620-015-3668-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  18 in total

1.  Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study.

Authors:  J B Felder; B I Korelitz; R Rajapakse; S Schwarz; A P Horatagis; G Gleim
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

2.  Recent Advances in Medical Diagnosis and Treatment.

Authors:  A H Douthwaite
Journal:  Br Med J       Date:  1938-05-28

Review 3.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

4.  Prostaglandin E₂ and polyenylphosphatidylcholine protect against intestinal fibrosis and regulate myofibroblast function.

Authors:  Angela C Baird; Frances Lloyd; Ian C Lawrance
Journal:  Dig Dis Sci       Date:  2015-01-29       Impact factor: 3.199

Review 5.  Prostaglandin E2 receptor distribution and function in the gastrointestinal tract.

Authors:  I Dey; M Lejeune; K Chadee
Journal:  Br J Pharmacol       Date:  2006-10-02       Impact factor: 8.739

6.  Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling.

Authors:  Steven Huang; Scott H Wettlaufer; Cory Hogaboam; David M Aronoff; Marc Peters-Golden
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-10-06       Impact factor: 5.464

Review 7.  New therapeutic avenues for treatment of fibrosis: can we learn from other diseases?

Authors:  Gerhard Rogler
Journal:  Dig Dis       Date:  2014-12-17       Impact factor: 2.404

8.  Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease.

Authors:  Valerie Pittet; Gerhard Rogler; Pierre Michetti; Nicolas Fournier; John-Paul Vader; Alain Schoepfer; Christian Mottet; Bernard Burnand; Florian Froehlich
Journal:  Digestion       Date:  2013-05-23       Impact factor: 3.216

9.  Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study.

Authors:  Wolfgang Stremmel; Annika Braun; Anja Hanemann; Robert Ehehalt; Frank Autschbach; Max Karner
Journal:  J Clin Gastroenterol       Date:  2010 May-Jun       Impact factor: 3.062

10.  Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance.

Authors:  Takatoshi Chinen; Kyoko Komai; Go Muto; Rimpei Morita; Naoko Inoue; Hideyuki Yoshida; Takashi Sekiya; Ryoko Yoshida; Kazuhiko Nakamura; Ryoichi Takayanagi; Akihiko Yoshimura
Journal:  Nat Commun       Date:  2011-02-08       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.